- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07577479
A Phase 1 Study of Single-Dose BW-50218 in Healthy Chinese Participants
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of A Single Dose of BW-50218 in Healthy Chinese Participants
A Phase 1 Study of Single-Dose BW-50218 in Healthy Chinese Participants
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of A Single Dose of BW-50218 in Healthy Chinese Participants
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Shanghai, Chiny
- Argo Investigative Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Capable of providing written informed consent and complying with all study procedures for the duration of the study.
- Body weight > 50 kg for males and > 45 kg for females; body mass index (BMI) within a range considered appropriate for study participation by the investigator.
- Female participants must be non-pregnant, non-lactating, and either of non-childbearing potential or using highly effective contraception.
- Male participants with partners of childbearing potential must agree to use effective contraception.
Exclusion Criteria:
- Any clinically significant chronic medical condition or clinically significant abnormality in physical examination that, in the opinion of the Investigator, makes the participant unsuitable for participation in the study.
- Recent hospitalization or a significant acute medical event.
- History of cancer or any long-term medical condition that the study doctor considers clinically relevant.
- Clinical laboratory findings outside of range which are deemed clinically significant by the investigator at screening or Day -1.
- Positive test for hepatitis B, hepatitis C, or HIV.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: BW-50218 Dose1
Single dose of BW-50218 injection (Dose 1) |
Solution for injection |
|
Eksperymentalny: BW-50218 Dose 2
Single dose of BW-50218 injection (Dose 2) |
Solution for injection |
|
Eksperymentalny: BW-50218 Dose 3
Single dose of BW-50218 injection (Dose 3) |
Solution for injection |
|
Komparator placebo: Saline Placebo
Single dose of Saline Placebo |
Solution for injection |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAES)
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
Evaluation of the number of participants with treatment-emergent adverse events and serious adverse events. The severity of AEs will be assessed and categorized according to the "Guidance for industry: Toxicity Grading Scale for Healthy Adultand Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials" (FDA, 2007). |
From baseline up to Day 360 (End of Study)
|
|
Hematology results (Platelets, 10^9/L) at each time point, including changes from baseline to Day 360 post dose will be summarized by treatment group.
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be flagged. |
From baseline up to Day 360 (End of Study)
|
|
Hematology results (concentration of Hemoglobin, g/L) at each time point, including changes from baseline to Day 360 post dose will be summarized by treatment group.
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be flagged. |
From baseline up to Day 360 (End of Study)
|
|
Chemistry results (Albumin, g/L) at each time point from baseline to Day 360 will be summarized bytreatment group.
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be flagged. |
From baseline up to Day 360 (End of Study)
|
|
Chemistry results (Alkaline Phosphatase, U/L; Alanine Aminotransferase, U/L; Aspartate Aminotransferase, U/L) at each time point from baseline to Day 360 will be summarized bytreatment group.
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be flagged. |
From baseline up to Day 360 (End of Study)
|
|
Chemistry results (Direct Bilirubin, umol/L) at each time point from baseline to Day 360 will be summarized bytreatment group.
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be flagged. |
From baseline up to Day 360 (End of Study)
|
|
Urinalysis results (Epithelial cells, crystals, casts, bilirubin) at each time point,including change from baseline to Day 360 post dose will be summarized in thetable by treatment group.
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be fagged. |
From baseline up to Day 360 (End of Study)
|
|
Vital signs (Blood pressures, millimeters of mercury) changes from Baselinevalues to Day 360 post dose will be summarized in the table by treatment group
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
Abnormal physical examination findings will be listed. |
From baseline up to Day 360 (End of Study)
|
|
Vital signs (Heart rate, beats per minute) changes from Baseline values to Day 360 post dose will be summarized in the table by treatment group.
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
Abnormal physical examination findings will be listed. |
From baseline up to Day 360 (End of Study)
|
|
Vital signs (Respiratory rate, times per minute) changes from Baseline values to Day 360 post dose will be summarized in the table by treatment group.
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
Abnormal physical examination findings will be listed. |
From baseline up to Day 360 (End of Study)
|
|
Vital signs (Temperature,degrees Celsius) changes from Baseline values to Day 360 post dose will be summarized in the table by treatment group.
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
Abnormal physical examination findings will be listed. |
From baseline up to Day 360 (End of Study)
|
|
Changes in ECG (PR Interval, msec; QRs Duration, msec;QT interval, msec; RR interval, msec; QTcF Interval, msec; ) from Baseline to Day 360 post-dose will be summarized.
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
12-lead ECGs will be summarized by visit and by treatment group, along with the changes from baseline.The summary of overall interpretation findings table presented counts and percentages for the reported results at Baseline and Day 360/time point. Result categories were ordered as "Normal", "Abnormal Not Clinically Significant (NCS)" and "Abnormal Clinically Significant (CS)"(categorical descriptive analysis). |
From baseline up to Day 360 (End of Study)
|
|
Changes in ECG (Mean heart rate, bpm ) from Baseline to Day 360 post-dose will be summarized.
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
12-lead ECGs will be summarized by visit and by treatment group, along with the changes from baseline.The summary of overall interpretation findings table presented counts and percentages for the reported results at Baseline and Day 360/time point. Result categories were ordered as "Normal", "Abnormal Not Clinically Significant (NCS)" and "Abnormal Clinically Significant (CS)"(categorical descriptive analysis). |
From baseline up to Day 360 (End of Study)
|
|
Change from Baseline in Physical Examination Findings
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
Assessment of clinically significant changes in physical examination findings |
From baseline up to Day 360 (End of Study)
|
|
Hematology results (Red blood cell count, 10^12/L) at each time point, including changes from baseline to Day 360 post dose will be summarized by treatment group.
Ramy czasowe: From baseline up to Day 360 (End of Study)
|
The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be flagged. |
From baseline up to Day 360 (End of Study)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax)
Ramy czasowe: From pre-dose up to Day 8
|
Evaluation of the maximum plasma concentration of BW-50218. |
From pre-dose up to Day 8
|
|
Time to Maximum Plasma Concentration (Tmax)
Ramy czasowe: From pre-dose up to Day 8
|
Evaluation of the time to reach maximum plasma concentration. |
From pre-dose up to Day 8
|
|
Area Under the Plasma Concentration-Time Curve (AUC)
Ramy czasowe: From pre-dose up to Day 8
|
Evaluation of AUc from time zero to 24 hours (AUC0-24), to 48 hours (AUC0-48), and to infinity (AUC0-inf) |
From pre-dose up to Day 8
|
|
Terminal Elimination Half-Life (t1/2)
Ramy czasowe: From pre-dose up to Day 8
|
Evaluation of the elimination half-life of BW-50218 |
From pre-dose up to Day 8
|
|
Urine Pharmacokinetic Parameters (Renal Clearance, CLr)
Ramy czasowe: From pre-dose up to 24 hours post-dose
|
Renal clearance calculated as CLr = CAe/Plasma AUC 0-24. Ae=cumulative amount excreted in urine (mg). AUC 0-24 = Area under the plasma concentration - time curve from 0 to 24 hours(e.g.mg*h/mL) |
From pre-dose up to 24 hours post-dose
|
Współpracownicy i badacze
Śledczy
- Dyrektor Studium: Yuqiong Li, Shanghai Argo Biopharmaceutical Co., Ltd.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- BW-50218-1002
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
A decision regarding sharing of de-identified IPD will be made by the Sponsor after study completion and will consider scientific merit, participant privacy, and regulatory requirements.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .